-
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress
PharmaSources
June 12, 2023
On June 12, 2023,Data of InnoCare’s robust pipelines were presented at the European Hematology Association 2023 Hybrid Congress.
-
Clinical Study Result of Orelabrutinib in Patients with R/R MCL Published by Blood Advances
PharmaSources
May 04, 2023
Blood Advances recently published the clinical study study result of BTK inhibitor orelabrutinib in Relapsed or Refractory Mantle Cell Lymphoma patients.
-
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
PharmaSources
April 20, 2023
April 20, 2023,InnoCare Pharma announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma .
-
InnoCare Releases 2022 Annual Results and Business Highlights
PharmaSources
March 29, 2023
28 March 2023,InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced 2022 annual results as of 31 December 2022.
-
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology
PharmaSources
February 07, 2023
American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
-
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
PharmaSources.com
December 20, 2022
InnoCare Pharma announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial.
-
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
PharmaSources.com
November 22, 2022
InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
-
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA
PharmaSources.com
September 06, 2022
So far, no BTK inhibitor has ever been approved for treating patients with R/R MZL in China, and hope that orelabrutinib can fill the gap in this therapeutic area.
-
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China
March 14, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced recently...
-
Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH
prnasia
December 14, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting...